Carcinogenic glutamic acid pyrolysis product in the dialysate of uremic patients treated by continuous ambulatory peritoneal dialysis.
By using a high-performance liquid chromatography (HPLC) method, we determined the contents of 2-amino-6-methyldipyrido[1,2-a:3', 2'-d] imidazole (Glu-P-1) and 2-aminodipyrido[1,2-a:3', 2'-d]imidazole (Glu-P-2) in the dialysate of patients with uremia. The total dialysate (approximately 6 liters) per day of the patients who had received continuous ambulatory peritoneal dialysis (CAPD) was examined. The amounts of Glu-P-1 and Glu-P-2 in the total dialysate per day were 552.2 +/- 266.9 pmole and 386.3 +/- 146.0 pmole (mean +/- SD, n = 10), respectively. The recoveries of Glu-P-1 and Glu-P-2 in the dialysate on our assay method were 68.2% and 54.3%, respectively. Based on the recoveries, the average amounts of Glu-P-1 and Glu-P-2 in the dialysate of uremic patients were assumed to be 809.7 pmole and 711.4 pmole, respectively.
D000328:Adult; D002851:Chromatography, High Pressure Liquid; D015314:Dialysis Solutions / Q000032:analysis*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000032:analysis* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009152:Mutagenicity Tests; D009153:Mutagens / Q000032:analysis* / Q000494:pharmacology; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D012486:Salmonella typhimurium / Q000187:drug effects; D014511:Uremia / Q000097:blood*
D015314:Dialysis Solutions; D007093:Imidazoles; D009153:Mutagens; C023785:2-amino-6-methyldipyrido(1,2-a-3',2'-d)imidazole; C023847:Glu-P-2